International Flavors & Fragrances
IFF
84.11
+0.19
+0.23%
International Flavors & Fragrances
US · IFF
#881 by market cap
Listed 1970
84.11
+0.19
+0.23%
Live - 5344 symbols - heartbeat 369s ago
· 2026-10-08 04:22
Pre-market
82.42
-2.01%
After-hours
84.11
0.00%
- Market cap
- 21.46B
- P/E (TTM)i
- 78.61
- P/Bi
- 1.54
- EPSi
- -1.41
- Div yieldi
- 1.90%
- 52W posi
- 84%
Reader sentiment
Are you bullish or bearish on IFF?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.56, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -5.17% YoY
Margins
- Gross margin
- 36.16%
- Operating margin
- 7.73%
- Net margin
- -3.32%
Key ratios & quality
- Enterprise valuei
- 26.96B
- Altman Z-Scorei
- 1.56
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.98B | 5.14B | 5.08B | 11.66B | 12.44B | 11.48B | 11.48B | 10.89B |
| Gross profit | 1.68B | 2.11B | 2.09B | 3.74B | 4.15B | 3.68B | 4.12B | 3.94B |
| Selling & admin expenses | 707.46M | 876.00M | 949.00M | 1.75B | 1.77B | 1.79B | 2.00B | 1.83B |
| Research & development | 311.58M | 346.00M | 357.00M | 629.00M | 603.00M | 636.00M | 671.00M | 694.00M |
| Operating profit | 587.78M | 698.00M | 587.00M | 625.00M | 1.05B | 578.00M | 848.00M | 842.00M |
| Pretax profit | 447.76M | 557.00M | 441.00M | 354.00M | -1.63B | -2.52B | 308.00M | -412.00M |
| Tax | 107.98M | 97.00M | 74.00M | 75.00M | 239.00M | 69.00M | 41.00M | -53.00M |
| Net profit | 339.78M | 460.00M | 367.00M | 279.00M | -1.86B | -2.59B | 267.00M | -359.00M |
| Basic EPS | 4 | 4 | 3 | 1 | -7 | -10 | 1 | -1 |
| Diluted EPS | 3.79 | 4.00 | 3.21 | 1.10 | -7.32 | -10.14 | 1.04 | -1.41 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.84B | 1.92B | 2.69B | 2.59B | 2.74B | 1.95B |
| Gross profit | 1.04B | 824.00M | 983.00M | 890.00M | 1.02B | 853.00M |
| Selling & admin expenses | 461.00M | 409.00M | 421.00M | 469.00M | 427.00M | 437.00M |
| Research & development | 164.00M | 170.00M | 174.00M | 174.00M | 166.00M | 170.00M |
| Operating profit | 267.00M | 163.00M | 242.00M | 113.00M | 279.00M | 164.00M |
| Pretax profit | -994.00M | 438.00M | 56.00M | 22.00M | 209.00M | 64.00M |
| Tax | 23.00M | -112.00M | 15.00M | -9.00M | 39.00M | 31.00M |
| Net profit | -1.02B | 599.00M | 41.00M | 31.00M | 170.00M | 51.00M |
| Basic EPS | -4 | 2 | 0 | 0 | 1 | 0 |
| Diluted EPS | -3.98 | 2.33 | 0.16 | 0.07 | 0.66 | 0.20 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.94B | 2.94B | 3.06B | 6.99B | 7.43B | 6.29B | 7.97B | 5.59B |
| Cash & ST investments | 634.90M | 606.82M | 650.00M | 711.00M | 483.00M | 703.00M | 469.00M | 590.00M |
| Inventory | 1.08B | 1.12B | 1.13B | 2.52B | 3.30B | 2.64B | 2.26B | 2.36B |
| Total assets | 12.89B | 13.29B | 13.56B | 39.66B | 35.52B | 30.98B | 28.72B | 25.54B |
| Total current liabilities | 1.13B | 1.55B | 1.90B | 3.63B | 3.73B | 3.76B | 4.35B | 3.93B |
| Short-term debt | 48.64M | 424.63M | 678.00M | 741.00M | 683.00M | 970.00M | 1.50B | 1.35B |
| Long-term debt | 4.50B | 4.00B | 3.78B | 10.77B | 10.37B | 9.19B | 7.56B | 4.74B |
| Total liabilities | 6,764,215,000.00 | 6,958,820,000.00 | 7,135,000,000.00 | 18,436,000,000.00 | 17,778,000,000.00 | 16,336,000,000.00 | 14,854,000,000.00 | 11,353,000,000.00 |
| Total equity | 6.13B | 6.33B | 6.42B | 21.22B | 17.74B | 14.64B | 13.87B | 14.19B |
| Retained earnings | 3.96B | 4.12B | 4.16B | 3.64B | 955.00M | -2.44B | -2.65B | -3.42B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 8.63B | 5.93B | 5.88B | 5.59B | 5.44B | 9.09B |
| Cash & ST investments | 613.00M | 816.00M | 621.00M | 590.00M | 562.00M | 569.00M |
| Inventory | 2.38B | 2.50B | 2.45B | 2.36B | 2.37B | 1.51B |
| Total assets | 28.27B | 26.12B | 25.77B | 25.54B | 25.14B | 25.15B |
| Total current liabilities | 4.61B | 3.18B | 4.07B | 3.93B | 3.65B | 4.41B |
| Short-term debt | 1.78B | 595.00M | 1.40B | 1.35B | 1.17B | 1.05B |
| Long-term debt | 7.60B | 5.68B | 4.74B | 4.74B | 4.74B | 4.74B |
| Total liabilities | 15,052,000,000.00 | 11,685,000,000.00 | 11,495,000,000.00 | 11,353,000,000.00 | 10,991,000,000.00 | 11,145,000,000.00 |
| Total equity | 13.21B | 14.44B | 14.27B | 14.19B | 14.15B | 14.01B |
| Retained earnings | -3.73B | -3.22B | -3.35B | -3.42B | -3.35B | -3.40B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 437.58M | 699.00M | 714.00M | 1.44B | 397.00M | 1.46B | 1.07B | 850.00M |
| Depreciation & amortization | 173.79M | 323.00M | 325.00M | 1.16B | 1.18B | 1.14B | 1.02B | 962.00M |
| Free cash flow | 264.16M | 457.00M | 522.00M | 1.04B | -109.00M | 952.00M | 602.00M | 254.00M |
| Dividends paid | -230.22M | -314.00M | -323.00M | -667.00M | -810.00M | -826.00M | -514.00M | -409.00M |
| Stock buybacks / issuance | -15.48M | -- | -- | -- | -- | 0 | 0 | -38.00M |
| Ending cash balance | 648.52M | 624.00M | 660.00M | 716.00M | 552.00M | 735.00M | 471.00M | 590.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 127.00M | 241.00M | 164.00M | 318.00M | 257.00M | 422.00M |
| Depreciation & amortization | 236.00M | 242.00M | 247.00M | 237.00M | 246.00M | 218.00M |
| Free cash flow | -52.00M | 146.00M | 30.00M | 130.00M | 92.00M | 284.00M |
| Dividends paid | -102.00M | -102.00M | -102.00M | -103.00M | -102.00M | -102.00M |
| Stock buybacks / issuance | 0 | 0 | -- | -- | -35.00M | -36.00M |
| Ending cash balance | 650.00M | 816.00M | 621.00M | 590.00M | 562.00M | 569.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.74 | 7.44 | 5.83 | 1.96 | -9.64 | -15.88 | 1.71 | -2.58 |
| ROA %i | 3.86 | 3.48 | 2.72 | 1.01 | -4.98 | -7.73 | 0.81 | -1.33 |
| ROIC %i | 6.30 | 5.37 | 4.43 | 2.25 | -5.17 | -8.34 | 2.10 | -0.73 |
| 5-year avg ROE %i | 21.30 | 17.22 | 12.99 | 8.35 | 2.84 | -2.10 | -3.21 | -4.90 |
| EBIT margin %i | 14.59 | 13.53 | 11.27 | 5.52 | -10.36 | -18.63 | 5.08 | -1.68 |
| FCF / sales %i | 6.64 | 8.89 | 10.27 | 8.92 | -- | 8.15 | 5.24 | 2.33 |
| Current ratioi | 2.61 | 1.90 | 1.61 | 1.92 | 1.99 | 1.67 | 1.83 | 1.42 |
| Quick ratioi | 1.39 | 1.05 | 0.93 | 0.81 | 0.71 | 0.74 | 0.55 | 0.71 |
| Debt / assetsi | 35.32 | 33.28 | 34.84 | 30.71 | 33.02 | 34.86 | 33.45 | 25.92 |
| LT debt / equityi | 74.66 | 64.30 | 64.09 | 54.25 | 62.56 | 67.26 | 58.65 | 37.25 |
| Interest coveragei | 4.38 | 5.03 | 4.35 | 2.22 | -3.84 | -5.63 | 1.91 | -0.80 |
| Revenue CAGR (3Y) %i | 9.58 | 18.15 | 14.37 | 43.10 | 34.26 | 31.19 | -0.49 | -4.34 |
| Net income CAGR (3Y) %i | -7.26 | 3.88 | 7.27 | -7.12 | -- | -- | -0.63 | -- |
| FCF CAGR (3Y) %i | -10.32 | 2.55 | 25.87 | 57.90 | -- | 22.18 | -16.66 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -6.08 | -2.74 | -3.25 | -2.58 | 6.05 | 1.95 |
| ROA %i | -2.84 | -1.41 | -1.69 | -1.33 | 3.09 | 1.08 |
| ROIC %i | -2.24 | -0.74 | -1.19 | -0.73 | 4.34 | 1.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.71 | -1.81 | -2.98 | -1.68 | 9.20 | -4.55 |
| FCF / sales %i | 4.98 | 4.95 | 3.19 | 2.33 | 3.69 | 4.97 |
| Current ratioi | 1.87 | 1.86 | 1.44 | 1.42 | 1.49 | 2.06 |
| Quick ratioi | 0.54 | 0.90 | 0.67 | 0.71 | 0.71 | 0.54 |
| Debt / assetsi | 35.06 | 26.22 | 25.96 | 25.92 | 25.59 | 24.82 |
| LT debt / equityi | 61.74 | 43.43 | 37.14 | 37.25 | 37.27 | 37.18 |
| Interest coveragei | -1.84 | -0.75 | -1.33 | -0.80 | 4.92 | -2.63 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Taste is the largest reported line at 35.21% of revenue, across 3 reported segments.
- No single line clears half of revenue; Scent is next at 34.03%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Taste35.21%
Scent34.03%
Health & Biosciences30.76%
Quote time 2026-10-08 04:22:38 · For reference only, not investment advice and not tailored to your situation.